Under the deals, Oxford will have access to Lophius’ UREA technology while Lophius will gain access to Oxford’s T-SPOT technology.
Oxford chief executive officer Dr. Peter Wrighton-Smith said, "We believe that Lophius’s UREA technology has distinct advantages over conventional methods of designing and producing antigens for T-cell based diagnostic test systems."
Financial details of the deals have not been revealed.
Lophius managing director Dr. Michael Lutz said, "This cooperation also confirms the commercial potential of our proprietary UREA technology platform which led to recent successful development of two CE-marked tests, namely T-Track CMV and T-Track EBV."